New combo therapy aims to tame aggressive leukemia with fewer side effects
NCT ID NCT07493161
First seen Apr 06, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This study is for people newly diagnosed with a specific type of leukemia called Ph+ ALL. It tests a treatment plan that uses lower doses of chemotherapy along with targeted drugs (venetoclax, blinatumomab, and olverembatinib) to see if it works well and causes fewer side effects. About 110 adults aged 14 and older will take part. The goal is to control the disease and keep it from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PH+ ALL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.